SIRT1 Attenuates Neuropathic Pain via CDK5-Kalirin-7 Signaling Pathway in Type 2 Diabetic Rats

Area of Science:

• Neuroscience
• Molecular Biology
• Pain Research

Background:

• Sirtuin 1 (SIRT1) plays a significant role in various animal models of neuropathic pain.
• Diabetic neuropathic pain (DNP) is characterized by diminished SIRT1 expression and altered signaling pathways.

Purpose of the Study:

• To investigate if upregulating SIRT1 expression through the CDK5-Kalirin-7 signaling pathway can alleviate pain in type 2 diabetic rats.
• To elucidate the role of the CDK5-Kalirin-7 pathway in the development of DNP.

Main Methods:

• Established a rat model of type 2 diabetes with peripheral nerve injury to simulate DNP.
• Administered SRT1720 (SIRT1 agonist) and Roscovitine (CDK5 antagonist) to assess pain behaviors (MWT, TWL).
• Analyzed protein expression levels of SIRT1, CDK5, Kalirin-7, p35, and NR2B in vivo and in vitro (BV2 and PC12 cells).

Main Results:

• Spinal SIRT1 expression was reduced in DNP rats; SRT1720 treatment alleviated pain behaviors.
• CDK5-Kalirin-7 pathway components (Kalirin-7, p-NR2B) were upregulated in DNP rats, with elevated CDK5 acetylation.
• Roscovitine treatment reduced pain behaviors and normalized the expression of key proteins in DNP models.

Conclusions:

• SIRT1 upregulation, particularly through the CDK5-Kalirin-7 pathway, effectively reduces pain in DNP.
• The CDK5-Kalirin-7 signaling pathway is a critical mediator in the progression of DNP.
• Targeting SIRT1 and the CDK5-Kalirin-7 pathway offers a potential therapeutic strategy for managing DNP.